---
title: "Cumin (Cuminum cyminum) & Black Cumin (Nigella sativa) — Clinical Monograph (Vector Store Ready)"
category: "Herbal / Spice Monograph"
tags:
  [
    "cuminum-cyminum",
    "nigella-sativa",
    "cumin",
    "black-cumin",
    "metabolic-syndrome",
    "type-2-diabetes",
    "weight-loss",
    "hyperlipidemia",
    "rheumatoid-arthritis",
    "allergic-rhinitis",
    "asthma",
    "skin-disease",
    "ibs",
    "vulvovaginal-candidiasis",
  ]
source: "Condensed and structured from the cumin monograph in the todo folder, which covers both Cuminum cyminum (true cumin) and Nigella sativa (black cumin) and synthesizes RCTs, meta-analyses and mechanistic studies on metabolic, inflammatory, GI and other indications."
---

## Main Topic

The term “cumin” can refer to two distinct botanicals with different chemistry and evidence bases:

- **Cuminum cyminum** (true cumin; Apiaceae) — culinary spice traditionally used for dyspepsia, flatulence and colic; modern trials focus on **glycemic control, weight loss, lipids, blood pressure, IBS, and vulvovaginal candidiasis**.
- **Nigella sativa** (black cumin; Ranunculaceae) — medicinal seed with a broad evidence base for **metabolic disorders, cardiovascular risk, inflammatory and autoimmune diseases, respiratory allergy/asthma and dermatologic conditions**, driven largely by thymoquinone.

The distinction is critical for retrieval and clinical reasoning, as their bioactive profiles, mechanisms and best-supported indications differ.

---

## Pharmacology & Mechanisms (Summary)

### Cuminum cyminum (True Cumin)

- **Key constituents**:

  - ~10% fixed oil, ~1.5% volatile oil rich in hydrocarbons and aldehydes.
  - Essential oil dominated by **cuminaldehyde** (~2.5–4.0% of seed) plus γ‑terpinene, p‑cymene, α/β‑pinene, limonene, linalool.

- **Mechanisms (preclinical)**:
  - **Insulinotropic**: cuminaldehyde/cuminol stimulate glucose-dependent insulin secretion via KATP channel closure and Ca²⁺ influx; protect β‑cells in STZ models.
  - **Enzyme modulation**: stimulates digestive enzymes (protease, lipase, amylase); may inhibit α‑glycosidase, slowing carbohydrate digestion.
  - **Metabolic signaling**: data suggest PPAR‑γ activation → ↑ GLUT‑4 and improved glucose uptake; possible **TRPA1 agonism** → appetite and glycemic regulation.
  - **Anti-inflammatory/antioxidant**: downregulates TLR4/NF‑κB; lowers Bax, TNF‑α, IL‑6; increases SOD, catalase, TAC and reduces MDA.
  - **Antimicrobial**: essential oil is bacteriostatic/bactericidal against MDR _S. aureus_ and _E. coli_, disrupts membranes, and shows quorum sensing inhibition (↓ virulence/biofilm genes).

### Nigella sativa (Black Cumin)

- **Key constituents**:

  - Volatile oil containing **thymoquinone (TQ)** (≈30–48% of oil), thymohydroquinone, dithymoquinone, carvacrol, p‑cymene, etc.
  - Fixed oil (32–40%), proteins, saponins, sterols (β‑sitosterol, campesterol), alkaloids (nigellidine, nigellicine).

- **Mechanisms (preclinical & translational)**:
  - **Anti-inflammatory**: inhibits **NF‑κB, STAT3, COX, 5‑LOX**, reducing TNF‑α, IL‑6, IL‑1β, ICAM‑1, VCAM‑1 and other mediators.
  - **Antioxidant**: activates Nrf2/ARE pathway → ↑ HO‑1, SOD, GPx, TAC; ↓ MDA.
  - **Metabolic**: reduces gluconeogenesis (↓ fructose‑1,6‑bisphosphatase, glucose‑6‑phosphatase); activates AMPK, improving insulin signaling and glucose uptake.
  - **Cardiovascular**: enhances NO production, improves endothelial function, lowers BP and modulates lipids.
  - **Antimicrobial/antiviral**: broad-spectrum activity vs bacteria, fungi and viruses; TQ MIC as low as 3 µg/mL vs _S. aureus_; in vitro and docking studies suggest anti‑coronavirus potential.

---

## Human Clinical Evidence — Cuminum cyminum

### Glycemic Control & Insulin Sensitivity

- RCTs of cumin essential oil (typically 50–100 mg/day for ~8 weeks) in T2DM show:
  - ↓ fasting blood sugar, ↓ HbA1c, ↓ fasting insulin and ↑ HOMA‑B in some trials.
  - Meta-analyses are **conflicting**: some report significant FBG reductions and QUICKI improvements; others find no consistent effect on FBG, HbA1c, insulin or HOMA‑IR.
  - Overall: evidence suggests **modest, adjunctive benefit**, not a reliable standalone therapy.

### Weight Loss & Anthropometrics

- Multiple RCTs in overweight/obese subjects:
  - Cumin capsules (75 mg 2–3×/day) for 8 weeks → weight loss ~1–2 kg and BMI reductions (~0.4–0.8 kg/m²) vs placebo; some studies show effects comparable to orlistat 120 mg.
  - Meta-analysis (7 RCTs) reports mean weight change ≈ −1.7 kg and BMI −0.67 kg/m².
  - Likely mechanisms: enzyme modulation, PPAR‑γ and TRPA1 effects.

### Lipids & Cardiometabolic Risk

- Trials using cumin powder (3–5 g/day) or combinations (e.g., cumin + lime) show:
  - ↓ TC, ↓ TG, ↓ LDL/VLDL, ↑ HDL in T2DM and metabolic syndrome populations.
  - Some studies, especially with low-dose essential oil, show **no significant lipid changes**.
  - Benefits appear strongest in metabolic dysfunction (T2DM, metabolic syndrome).

### Blood Pressure

- In metabolic syndrome, essential oil (e.g., 225 mg/day) or capsules improved:
  - ↓ systolic and/or diastolic blood pressure vs baseline/placebo in short-term (≈8 weeks) RCTs.

### GI & Other Indications

- **IBS**:

  - RCT with 20 drops/day of 2% cumin essential oil for 4 weeks → significant reductions in abdominal pain, bloating and incomplete defecation scores.

- **Vulvovaginal candidiasis**:
  - Vaginal suppositories containing cumin saponins were as effective as clotrimazole in symptom resolution; Candida negative in ≈70% post-treatment.

---

## Human Clinical Evidence — Nigella sativa

> The monograph text contains extensive data; here we retain the main clinically relevant signals.

### Glycemic Control & Metabolic Syndrome

- Meta-analyses (≈30 RCTs) show:

  - ↓ fasting blood glucose (~15 mg/dL) and ↓ HbA1c (~0.45%) in prediabetes and T2DM.
  - Mixed results for fasting insulin and HOMA‑IR; effects likely via improved insulin sensitivity and hepatic glucose output rather than β‑cell stimulation.

- **Metabolic syndrome / NAFLD**:
  - Trials using 2–3 g/day seed powder or 5 mL/day oil demonstrate improvements in:
    - Weight, BMI, waist circumference.
    - FBG, HbA1c, LDL, TG and sometimes HDL.
    - Liver enzymes and hepatic steatosis in NAFLD.

### Lipids & Cardiovascular Risk

- Meta-analyses (≈50 RCTs):
  - ↓ LDL‑C (~18 mg/dL), ↓ TC, ↓ TG, modest ↑ HDL‑C.
  - Benefits seen across T2DM, NAFLD, metabolic syndrome and general dyslipidemia populations.

### Inflammatory & Autoimmune Conditions

- **Rheumatoid arthritis**:

  - 500 mg oil BID for ~8 weeks → ↓ DAS28, ↓ swollen/tender joint counts and improved morning stiffness versus placebo.

- **Other inflammatory diseases**:
  - Trials show reductions in CRP, TNF‑α, IL‑6 and other markers in various chronic conditions.

### Respiratory & Allergic Disease

- **Allergic rhinitis**:

  - Seed powder (~250 mg TID) or oil (15–30 mg/kg/day; nasal drops in some studies) over 2–4 weeks improves nasal congestion, rhinorrhea, sneezing and sleep, sometimes comparable to standard antihistamines or montelukast.

- **Asthma**:
  - Oral oil or seed powder as adjunctive therapy improves symptom scores and some lung function parameters; evidence modest but consistent across small RCTs.

### Dermatologic & Other Applications

- **Skin disease**:

  - Topical 5–10% N. sativa oil/gel improves acne, eczema, vitiligo and other dermatoses in RCTs; meta-analyses show pooled OR for improvement ~4.6 vs control.

- Other reported benefits include improved semen parameters in male infertility, reduced seizure frequency in pediatric epilepsy, and hepatoprotective effects in hepatitis C; evidence quality varies.

---

## Dosing & Administration (Adults)

> Many trials inadequately report standardization; doses below follow studied regimens.

### Cuminum cyminum

- **Metabolic & weight-loss indications**:

  - Essential oil: 50–100 mg/day (glycemic trials); 75 mg TID (weight-loss trials).
  - Powder: 3–5 g/day (often mixed with yogurt or diet interventions).
  - Herbal infusion: ~2 g seed in 200 mL water twice daily.

- **IBS**:

  - 20 drops/day of 2% essential oil (often divided doses) for ≈4 weeks.

- **Vulvovaginal candidiasis**:
  - Cumin saponin vaginal suppositories once daily for ~6 days in RCTs.

### Nigella sativa

- **Metabolic & cardiovascular**:

  - Seed powder: 1–3 g/day, often 2 g once daily.
  - Cold-pressed oil: 1–5 mL/day (commonly 2.5 mL BID or 5 mL once daily).
  - Standardized TQ extracts (examples from trials): 200–400 mg/day with defined TQ percentages (e.g., 5–10% TQ).

- **RA & inflammatory conditions**:

  - Oil capsules: 500 mg BID (~1 g/day) for 8–12 weeks.

- **Allergic rhinitis / asthma**:

  - Seed powder: 250–500 mg TID.
  - Oil: 15–30 mg/kg/day orally or 2 drops per nostril TID in nasal formulations.

- **Dermatologic (topical)**:
  - 5–10% N. sativa oil in gel/cream, applied BID to affected lesions for 8–12 weeks.

---

## Safety, Contraindications & Interactions

### Cuminum cyminum

- Generally well tolerated at doses used in trials; occasional GI discomfort.
- **Cautions**:
  - Potential additive hypoglycemic effects with antidiabetic drugs.
  - Theoretical risk of enhanced effects of antihypertensives and lipid-lowering agents; monitor.

### Nigella sativa

- Generally safe in short- to medium-term trials (up to 12 months) with doses outlined above; mild GI symptoms most common.
- **Cautions**:
  - TQ interacts with CYP enzymes and is highly protein bound; potential for drug interactions (e.g., with narrow therapeutic index drugs).
  - Long-term safety data beyond 1–2 years are limited.
  - Avoid in individuals with known allergy to Ranunculaceae; consider patch testing for topical preparations.

---

## Quality, Standardization & Adulteration

- **Nigella sativa**:

  - TQ content in commercial oils varies ~27‑fold (≈0.07–1.88%); clinical effects depend strongly on TQ dose.
  - Prefer products with **assayed TQ content** (e.g., defined % TQ) and third-party testing.

- **Cuminum cyminum**:
  - Quality judged by essential oil profile (cuminaldehyde %) but rarely declared on labels; choose reputable manufacturers; essential oil vs powder forms differ in bioactive content.

Clinicians should factor in this variability when interpreting evidence or making dosing decisions.

---

## Clinical Use Summary

- **Cuminum cyminum**:

  - Best positioned as an **adjunctive agent** for weight management and modest improvements in glucose and lipid parameters, particularly in overweight T2DM/metabolic syndrome populations; also supportive for IBS and some infectious indications (e.g., vulvovaginal candidiasis) with evidence from small RCTs.

- **Nigella sativa**:
  - Supported by a large if heterogeneous clinical literature for **metabolic syndrome, T2DM, dyslipidemia, RA, allergic rhinitis, asthma and skin diseases**.
  - Acts primarily as an anti-inflammatory, antioxidant and metabolic modulator with broad but generally modest effect sizes; should augment, not replace, standard-of-care therapies.

Both spices benefit from **better PK data, standardization and long-term safety studies**. Until then, they should be used in clearly defined adjunctive roles, with attention to product quality and potential interactions.
